HCC1395Homo sapiens (Human)Cancer cell line

Also known as: Hamon Cancer Center 1395, SCC-1395, HCC-1395

🤖 AI SummaryBased on 13 publications

Quick Overview

Human breast cancer cell line with unknown tissue origin and disease context.

Detailed Summary

HCC1395 is a human breast cancer cell line with unknown tissue origin and disease context. It is part of a large panel of cancer cell lines used for research, but specific details about its tissue of origin, disease type, and cell type are not available in the provided data. This cell line may be used in studies related to cancer biology, drug sensitivity, and genetic profiling, given its inclusion in comprehensive datasets like the Cancer Cell Line Encyclopedia (CCLE) and other large-scale studies. However, without additional information, its specific applications and characteristics remain to be determined.
Generated on 6/16/2025

Basic Information

Database IDCVCL_1249
SpeciesHomo sapiens (Human)
Tissue SourceBreast[UBERON:UBERON_0000310]

Donor Information

Age43
Age CategoryAdult
SexFemale
Racecaucasian
Subtype Featuresbasal_B TNBC

Disease Information

DiseaseBreast ductal carcinoma
LineageBreast
SubtypeBreast Invasive Ductal Carcinoma
OncoTree CodeIDC

DepMap Information

Source TypeATCC
Source IDACH-000699_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg175His (c.524G>A)UnspecifiedSomatic mutation acquired during proliferationfrom parent cell line YCC-3

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D10S1248
15
D12S391
20,21
D13S317
9
D16S539
11
D18S51
14
D19S433
13
D1S1656
17.3
D21S11
31,32.2
D22S1045
16
D2S1338
23,24,25
D2S441
11
D3S1358
15
D5S818
11
D7S820
10
D8S1179
14
FGA
21
Penta D
12
Penta E
7,12
TH01
9.3
TPOX
11
vWA
15
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.

Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.

J. Proteome Res. 16:1391-1400(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Modeling precision treatment of breast cancer.";

Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.

Genome Biol. 14:R110.1-R110.14(2013).

Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.

Breast Cancer Res. Treat. 142:237-255(2013).

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.

Martens J.W.M.

Breast Cancer Res. 15:R33.1-R33.17(2013).

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.

Chavez K.J., Garimella S.V., Lipkowitz S.

Breast Dis. 32:35-48(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Pollack J.R.

PLoS ONE 4:E6146-E6146(2009).

The genomic landscapes of human breast and colorectal cancers.";

Vogelstein B.

Science 318:1108-1113(2007).

The consensus coding sequences of human breast and colorectal cancers.

Vogelstein B., Kinzler K.W., Velculescu V.E.

Science 314:268-274(2006).

High-resolution analysis of DNA copy number using oligonucleotide microarrays.

Weber B., Shapero M.H., Wooster R.

Genome Res. 14:287-295(2004).

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Edwards P.A.W., Chaffanet M.

Genes Chromosomes Cancer 37:333-345(2003).

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

Comparison of features of human breast cancer cell lines and their corresponding tumors.

Gazdar A.F.

Clin. Cancer Res. 4:2931-2938(1998).

Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.

Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.

Int. J. Cancer 78:766-774(1998).